TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06291103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to Belatacep
Description: CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment (SOC regimen) with Tacrolimus
Description: Tacrolimus will be continued until kidney graft survival with objective of whole blood through levels between 6 and 8 ng/mL
Study: NCT05973994

Intervention type: DEVICE
Intervention: intravascular lithotripsy with Shockwave coronary system
Description: OCT acquistion is performed at baseline. Then the IVL catheter will be passed across the lesion over the guidewire. Atherectomy or cutting/scoring balloons is not permitted per protocol. The IVL procedure is considered successful when a residual stenosis \<50% by visual estimate after IVL alone is achieved. After IVL procedure, one OCT imaging acquisition must be performed. If the residual stenosis is ≥50% following IVL, noncompliant balloon dilatation will be performed prior to stenting and OCT images repeated accordingly. Subsequent stent implantation will be performed per local standard of care at the discretion of the operator. Following stent implantation, high pressure post-dilatation is recommended and OCT imaging acquisition must be performed to assess stent apposition for secondary end point.
Study: NCT06505057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
Description: Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
Study: NCT06266858

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: UCG
Description: UCG is the most common imaging modality to assess the mitral regurgitation in clinical and also is the primary modality recommended by guidelines. At the beginning of the study, the fasting patients receive UCG in the different situation such as pre-anaesthetic, post-anaesthetic and post-rehydration.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CMR
Description: CMR may be more accurate than UCG in assessing MR severity. In another time, the patients receive CMR.
Study: NCT04937582

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognitive assessment
Description: Complete cognitive and psychological assessment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognitive assessment
Description: Complete cognitive and psychological assessment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric evaluation
Description: Psychiatric consultation if necessary
Study: NCT06266858

Intervention type: OTHER
Group type: OTHER
Intervention: fasting
Description: At the beginning of the study, the patients need to fast when receive UCG.

Intervention type: OTHER
Group type: OTHER
Intervention: fasting
Description: At the beginning of the study, the patients need to fast when receive UCG.

Intervention type: OTHER
Group type: OTHER
Intervention: fasting
Description: At the beginning of the study, the patients need to fast when receive UCG.
Study: NCT05073718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid
Description: In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04884737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mepilex Border Flex® (MBF) dressing
Description: A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
Study: NCT06020651

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Arterial Doppler for Flow Mediated Reserve measurement
Description: Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arterial Doppler for Flow Mediated Reserve measurement
Description: Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arterial Doppler for Flow Mediated Reserve measurement
Description: Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arterial Doppler for Flow Mediated Reserve measurement
Description: Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs
Study: NCT05344300

Intervention type: OTHER
Intervention: Temperature-measurement in lungs under sauna bath
Description: Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.

Intervention type: OTHER
Intervention: Temperature-measurement in lungs under sauna bath
Description: Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
Study: NCT04937582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric evaluation
Description: Psychiatric consultation if necessary (before the end of their participation in the study)
Study: NCT04897841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline
Description: post-surgical saline
Study: NCT06027294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: A cuff will be inflated to a pressure of 225 mmHg.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ischemic Conditioning
Description: A cuff will be inflated to a pressure of 225 mmHg.
Study: NCT06180772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT FIRST
Description: High intensity sports drills and games
Study: NCT04897841

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: post-surgical saline
Study: NCT06554925

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: The difference in males and females undergoing cardiac surgery of all types

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: The difference in males and females undergoing cardiac surgery of all types
Study: NCT05647967

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Each patient underwent ultrasound after admission of ICU.
Study: NCT03915613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R
Description: The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose.
Study: NCT05058560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: tislelizumab, 200 mg IV Q3W, up to one year.
Study: NCT03915613

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diluent
Description: The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose.
Study: NCT05213715

Intervention type: OTHER
Intervention: assessment
Description: assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity

Intervention type: OTHER
Intervention: assessment
Description: assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity

Intervention type: OTHER
Intervention: assessment
Description: assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity
Study: NCT04680871

Intervention type: DEVICE
Intervention: In-Ear Sensor
Description: The device will passively monitor participants' biometrics

Intervention type: DEVICE
Intervention: In-Ear Sensor
Description: The device will passively monitor participants' biometrics
Study: NCT05754281

Intervention type: DEVICE
Intervention: 2nd Gen LabPatch Glucose Sensing System
Description: I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements
Study: NCT06613074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ali Pay intelligent navigation applet
Description: The intelligent navigation applet comprises of three function modules:~1. Stroke knowledge public education: information regarding prevention and emergency treatment of stroke would be push to users\&#39; mobile phones regularly;~2. Stroke recognition: questionaires, voice interaction, and facial recognition are employed to identify patients with AIS and large vessel occlusion;~3. Hospital recommendation: this module combines real-time traffic and average in-hopital delay of each stroke center nearby, recommending the stroke center in which patients are mostly likely to receive reperfusion therapy
Study: NCT06676111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
Study: NCT06496958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 insufflation with an abdominal compression device
Description: For participants randomized to the intervention group, the back brace support belt, Maxbelt (me3 type, Nippon Sigmax Co., Tokyo, Japan), will be applied around the circumference of the lower abdomen. Five sizes of Maxbelt will be employed in this study. According to the manufacturer, the ultra small-size (XS-size) belt will be used in those patients with an abdominal circumference of 55 cm-65 cm, the small-size (S-size) belt will be used in those patients with an abdominal circumference of 65 cm-75 cm, the medium-size (M-size) belt will be used for a circumference of 75 cm-85 cm, the large-size (L-size) belt will be used for a circumference of 85 cm-95 cm, and the ultra large-size (XL-size) will be used for a circumference of 95 cm-105 cm. Once applied, participants will be asked to assess and confirm that the belt is fastened tightly but not uncomfortably.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO2 insufflation with a sham abdominal compression device
Description: The study coordinator will fit the sham device in a private bay alone with the patient. For participants randomized to the sham control group, a larger-sized Maxbelt with loose fitting will be used as a sham device. The L-size Maxbelt will be used in those patients with an abdominal circumference of 55 cm-71 cm, the XL-size Maxbelt will be used in in those patients with an abdominal circumference of 72 cm-88 cm, and the 2 XL-size Maxbelt will be used in in those patients with abdominal circumference 89 cm-105 cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange colonoscopy
Description: In those patients assigned to the water exchange (WE) group, the air pump will be turned off during the insertion phase of colonoscopy, while the colon is irrigated with warm-to-touch distilled water or half normal saline using a flushing pump. The WE approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Any encountered air pockets will be aspirated to ensure optimal WE maneuvers in salvage cleaning.
Study: NCT06631222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: The therapeutic patient education (TPE) program was based on a biobehavioral approach and was divided into the following three parts: cognitive, operant, and respondent. The purpose of the TPE program was to modify erroneous beliefs about pain and disability, as well as to provide coping strategies and improve patient self-efficacy through a graded activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sub-occipital inhibitory pressure
Description: The suboccipital musculature will be palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure was applied, pushing the atlas anteriorly. The occiput will be rested on the hands of the therapist while the atlas is supported by the fingertips. Finger pressure will be maintained for 10 minutes to produce the proposed therapeutic effect of inhibiting the suboccipital soft tissues.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sub-occipital inhibitory pressure
Description: The suboccipital musculature will be palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure was applied, pushing the atlas anteriorly. The occiput will be rested on the hands of the therapist while the atlas is supported by the fingertips. Finger pressure will be maintained for 10 minutes to produce the proposed therapeutic effect of inhibiting the suboccipital soft tissues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep friction massage
Description: Friction massage is performed with the fingertips placed on the trigger points. Pressure was applied and the fingertips move in a circular manner, while the pressure is gradually increased. This massage will be applied until the patient report a reduction in pain at the trigger point
Study: NCT04419181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Dose: 75 mg/m2 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Dose: 75 mg/m2 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose: area under the concentration-time curve \[AUC\] 6 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose: area under the concentration-time curve \[AUC\] 6 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Dose: 840-mg loading dose, 420-mg maintenance dose q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Dose: 840-mg loading dose, 420-mg maintenance dose q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Dose: 3.6mg/kg q3w
Study: NCT04743765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated medical clearance and surgery
Description: Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
Study: NCT06114329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL01211
Description: AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.
Study: NCT04789967

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Imagery
Description: Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
Study: NCT05757076

Intervention type: PROCEDURE
Intervention: Blood test for ARR
Description: Blood test for calculating aldosterone and renin ratio (ARR)
Study: NCT04789967

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Audiobook
Description: Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
Study: NCT06004869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)
Description: an integrated system based on an existing multicomponent cognitive behavioural therapy for insomnia (CBT-I) and EMA app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help cognitive behavioural therapy for insomnia
Description: An mobile app that delivers CBT-I content.
Study: NCT04865484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical resection of fibrostenotic area (\>4cm)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: Surgical resection of fibrostenotic area (\>4cm)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic stricturotomy
Description: Endoscopic stricturotomy of fibrostenotic area (≤4cm)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strictureplasty
Description: Strictureplasty of fibrostenotic area (≤4cm)
Study: NCT05589454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium tablets 80mg
Description: Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium tablets 20mg
Description: Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Study: NCT05104476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF82422
Description: Solution for infusion
Study: NCT05148780

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab Sample
Description: Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.
Study: NCT05039723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiesse, Xeomin, Belotero
Description: Rejuvenation with Radiesse, Xeomin, Belotero
Study: NCT04710017

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic acid
Description: will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Medroxyprogesterone Acetate 150 MG/ML
Description: will be given MPA at 150 mg once intramuscular injection
Study: NCT04722094

Intervention type: DIAGNOSTIC_TEST
Intervention: Full periodontal chart
Description: A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.

Intervention type: OTHER
Intervention: Saliva sampling
Description: Saliva samples for miRNAs detection will be taken before starting the visit.
Study: NCT04800224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Brazilian Green Propolis Extract
Description: 900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 900mg/day of Placebo for 10 days.
Study: NCT05928364

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal mucosa for proximal ureter stricture
Description: Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping